Report for: Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)

Title	Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)
Published in	Trials, December 2019
DOI	10.1186/s13063-019-3951-x
Pubmed ID	31856909
Authors	Elizabeth Ahern, Annette Cubitt, Emma Ballard, Michele W. L. Teng, William C. Dougall, Mark J. Smyth, David Godbolt, Rishendran Naidoo, Amanda Goldrick, Brett G. M. Hughes

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.

Country	Count	As %
Australia	2	67%
Italy	1	33%

Type	Count	As %
Members of the public	2	67%
Practitioners (doctors, other healthcare professionals)	1	33%

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	61	100%

Readers by professional status	Count	As %
Student > Ph. D. Student	9	15%
Student > Master	7	11%
Other	7	11%
Unspecified	6	10%
Student > Doctoral Student	5	8%
Other	13	21%
Unknown	14	23%

Readers by discipline	Count	As %
Medicine and Dentistry	22	36%
Unspecified	6	10%
Agricultural and Biological Sciences	5	8%
Biochemistry, Genetics and Molecular Biology	4	7%
Nursing and Health Professions	3	5%
Other	8	13%
Unknown	13	21%

Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label…